Iambic Therapeutics

Bayer and Iambic announced a small-molecule drug discovery collaboration in which Bayer will use Iambic’s AI platform, including Enchant and NeuralPLexer, to identify entry points and differentiated molecules for hard-to-drug targets.

Iambic announced it was selected for CNBC’s Disruptor 50 list for the second year in a row and provided context on its approach to AI and automation in drug discovery.

Iambic announced a multi-year technology and discovery collaboration agreement with Takeda. Iambic said Takeda would receive access to NeuralPLexer and Iambic would receive upfront/research/technology access payments plus success-based payments that could exceed $1.7B, along with potential royalties.

Iambic announced raising over $100 million in an oversubscribed financing round with support from multiple new and existing investors. The company linked the timing to its recent clinical data communications and a clinical collaboration with Jazz Pharmaceuticals.

Iambic announced entering a research collaboration and drug supply agreement with Jazz Pharmaceuticals for evaluation of IAM1363 in combination with zanidatamab in HER2-positive breast cancer patients previously treated with trastuzumab deruxtecan.

Iambic announced clinical data from IAM1363-01, describing monotherapy activity, safety, and tolerability across HER2-altered cancers and linking the results to its AI-discovered profile.

Iambic announced submitting an Investigational New Drug (IND) application to the FDA to initiate a Phase 1 clinical study evaluating IAM1363, positioned as the first asset from the company’s AI-driven platform to reach IND submission.

Iambic announced closing an oversubscribed $100 million Series B co-led by Ascenta Capital and Abingworth, and including investors such as NVIDIA and others. The company also described intended platform and clinical development use of the financing.